四价减毒活登革疫苗在成人中安全性和免疫原性的1期双盲随机安慰剂对照研究
在60名18至45岁健康成人中开展的1期双盲随机安慰剂对照研究,按2:1随机接受单剂次四价减毒活登革疫苗或安慰剂。疫苗组23人(59%)出现登革病毒血症;第57天四个血清型中和抗体GMT为66.76至293.84,第181天仍高于基线;安慰剂组抗体无变化。单剂疫苗安全耐受,多数受试者产生三价或四价血清阳转。
要点
- 疫苗组23人(59%)接种后出现登革病毒血症,多数在第9天和第11天。
- 第57天疫苗组四个血清型中和抗体GMT为66.76至293.84,第181天仍高于基线。
- 截至第85天血清阳转率DENV1为79.5%、DENV2为100%,安慰剂组无人阳转。
核心结论
- 单剂登革疫苗在成人中安全且耐受良好,具有高度免疫原性,多数受试者产生三价或四价血清阳转和血清阳性。
研究设计与样本
- 1期双盲随机安慰剂对照研究,在60名18至45岁健康成人中开展,按2:1随机接受单剂皮下注射四价减毒活登革疫苗(n=40)或安慰剂(n=20)。
- 安全性通过接种后21天内非 solicited 不良事件和 solicited 反应、整个180天研究期间的严重不良事件评估。
- 免疫原性采用蚀斑减少中和试验(PRNT)评估疫苗匹配的野生病毒血清型DENV1至DENV4,在基线及接种后第56、84、180天检测;对31名受试者亚组在第1天和第85天采用循环野生型DENV1至DENV4进行PRNT。
主要发现
- 疫苗组23人(59%)接种后出现任一血清型的登革病毒血症,多数在第9天和第11天。
- 基线时除疫苗组4人和安慰剂组2人外,两组所有受试者对四个血清型的登革PRNT50均为阴性。
- 第57天疫苗组四个血清型中和抗体GMT范围为66.76(95%CI 36.63,121.69)至293.84(95%CI 192.25,449.11)。
- 第181天疫苗组滴度虽下降但仍远高于基线,安慰剂组接种后滴度无变化。
- 截至第85天血清阳转率DENV1为79.5%、DENV2为100%,安慰剂组无人血清阳转;采用野生登革血清型PRNT时两组趋势相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dengue fever is an important public health problem, especially in Asia and South America. A tetravalent live attenuated dengue vaccine was manufactured in India after receipt of vaccine strains from NIAID, NIH, USA. METHODS: This was a Phase 1, double-blind, randomized, placebo-controlled study performed in 60 healthy adults of 18 to 45 years. Participants were randomized 2:1 to receive a single subcutaneous injection of either a tetravalent live attenuated dengue vaccine or placebo. Safety was assessed by unsolicited adverse events (AEs) and solicited reactions through 21 days after vaccination and serious adverse events (SAEs) through the entire study period of 180 days. Dengue viremia was assessed at baseline and on day 9, 11 and 13 post-vaccination using a plaque assay. Immunogenicity was assessed using the plaque reduction neutralization test (PRNT) assay using vaccine-matched wild virus serotypes (DENV 1, DENV 2, DENV 3 and DENV 4) at baseline and on 56-, 84- and 180-days post-vaccination. PRNT assay using circulating wild type DENV 1, DENV 2, DENV 3 and DENV 4 were done on day 1 and day 85 for a subset of 31 participants. RESULTS: 60 participants were randomized to receive dengue vaccine (n = 40) or placebo (n = 20). 23 participants (59 %) showed DENV vaccine viremia post- vaccination for any of the four serotypes with majority on day 9 and day 11. At baseline, all participants were naïve by dengue PRNT50 for all four serotypes in both the study groups except for four in the dengue vaccine group and two in the placebo group. On day 57, the GMTs of neutralizing antibodies ranged from 66.76 (95 % CI 36.63, 121.69) to 293.84 (95 % CI 192.25, 449.11) for all four serotypes in the dengue vaccine group. On day 181 though the titers declined, they still remained much higher than the baseline. The titers in the placebo group did not change after vaccination. Seroconversion through day 85 ranged from 79.5 % for DENV 1 to 100 % for DENV2 while in the placebo group, no participant showed seroconversion through day 85. Similar trends were noted when PRNT was done using wild DENV serotypes in both vaccine and placebo groups. Among solicited reactions, injection site erythema, rash, headache, fatigue, myalgia and arthralgia were reported more frequently in the vaccine group than placebo group. All solicited reactions were of grade 1 or grade 2 severity and completely resolved. One unrelated serious adverse event was reported in the vaccine group. CONCLUSION: A single dose of dengue vaccine was safe and well tolerated in adults. The vaccine was highly immunogenic with trivalent or tetravalent seroconversion and seropositivity in most of the participants. The study was funded by Serum Institute of India Pvt. Ltd., Pune, India. CLINICALTRIALS: gov: NCT04035278.
引用
- Gunale B, Farinola N, Yeolekar L, et al. A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults. Vaccine. 2023. PMID: 37532611. doi:10.1016/j.vaccine.2023.07.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。